Thomson Reuters Earnings Calls
| Release date | May 05, 2026 |
| EPS estimate | $1.18 |
| EPS actual | $1.23 |
| EPS Surprise | 4.24% |
| Revenue estimate | 2.003B |
| Revenue actual | 2.043B |
| Revenue Surprise | 1.99% |
| Release date | Feb 05, 2026 |
| EPS estimate | $1.09 |
| EPS actual | $1.07 |
| EPS Surprise | -1.83% |
| Revenue estimate | 2.013B |
| Revenue actual | 2.002B |
| Revenue Surprise | -0.521% |
| Release date | Nov 04, 2025 |
| EPS estimate | $0.81 |
| EPS actual | $0.85 |
| EPS Surprise | 4.94% |
| Revenue estimate | 1.778B |
| Revenue actual | 1.802B |
| Revenue Surprise | 1.34% |
| Release date | Aug 06, 2025 |
| EPS estimate | $0.83 |
| EPS actual | $0.87 |
| EPS Surprise | 4.82% |
| Revenue estimate | 1.808B |
| Revenue actual | 1.803B |
| Revenue Surprise | -0.256% |
Last 4 Quarters for Thomson Reuters
Below you can see how TRI performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 06, 2025 |
| Price on release | $182.90 |
| EPS estimate | $0.83 |
| EPS actual | $0.87 |
| EPS surprise | 4.82% |
| Date | Price |
|---|---|
| Jul 31, 2025 | $204.18 |
| Aug 01, 2025 | $204.35 |
| Aug 04, 2025 | $207.13 |
| Aug 05, 2025 | $203.07 |
| Aug 06, 2025 | $182.90 |
| Aug 07, 2025 | $184.51 |
| Aug 08, 2025 | $182.89 |
| Aug 11, 2025 | $177.61 |
| Aug 12, 2025 | $173.08 |
| 4 days before | -10.42% |
| 4 days after | -5.37% |
| On release day | 0.88% |
| Change in period | -15.23% |
| Release date | Nov 04, 2025 |
| Price on release | $149.12 |
| EPS estimate | $0.81 |
| EPS actual | $0.85 |
| EPS surprise | 4.94% |
| Date | Price |
|---|---|
| Oct 29, 2025 | $155.33 |
| Oct 30, 2025 | $157.00 |
| Oct 31, 2025 | $155.55 |
| Nov 03, 2025 | $158.25 |
| Nov 04, 2025 | $149.12 |
| Nov 05, 2025 | $146.51 |
| Nov 06, 2025 | $141.23 |
| Nov 07, 2025 | $139.81 |
| Nov 10, 2025 | $137.79 |
| 4 days before | -4.00% |
| 4 days after | -7.59% |
| On release day | -1.75% |
| Change in period | -11.29% |
| Release date | Feb 05, 2026 |
| Price on release | $89.75 |
| EPS estimate | $1.09 |
| EPS actual | $1.07 |
| EPS surprise | -1.83% |
| Date | Price |
|---|---|
| Jan 30, 2026 | $112.43 |
| Feb 02, 2026 | $110.80 |
| Feb 03, 2026 | $93.45 |
| Feb 04, 2026 | $95.08 |
| Feb 05, 2026 | $89.75 |
| Feb 06, 2026 | $89.50 |
| Feb 09, 2026 | $90.76 |
| Feb 10, 2026 | $92.34 |
| Feb 11, 2026 | $90.65 |
| 4 days before | -20.18% |
| 4 days after | 1.01% |
| On release day | -0.272% |
| Change in period | -19.37% |
| Release date | May 05, 2026 |
| Price on release | $95.46 |
| EPS estimate | $1.18 |
| EPS actual | $1.23 |
| EPS surprise | 4.24% |
| Date | Price |
|---|---|
| Apr 29, 2026 | $94.81 |
| Apr 30, 2026 | $97.25 |
| May 01, 2026 | $95.95 |
| May 04, 2026 | $95.75 |
| May 05, 2026 | $95.46 |
| May 06, 2026 | $91.75 |
| May 07, 2026 | $93.37 |
| May 08, 2026 | $92.94 |
| May 11, 2026 | $89.22 |
| 4 days before | 0.689% |
| 4 days after | -6.54% |
| On release day | -3.89% |
| Change in period | -5.89% |
Thomson Reuters Earnings Call Transcript Summary of Q1 2026
Thomson Reuters delivered a strong start to 2026 with first-quarter organic revenue up 8% (Big 3 segments +9%), adjusted EBITDA of $881M (+9%) and adjusted EPS of $1.23 (+10%). The company reaffirmed full-year 2026 guidance: organic revenue growth of 7.5%–8% (Big 3 ~9.5%), adjusted EBITDA margin improvement of ~100 bps to ~40%, and ~ $2.1B of free cash flow. Key growth drivers are AI-enabled products (Westlaw Advantage, CoCounsel and other AI offerings), double-digit growth in several product lines (CoCounsel, Pagero, SafeSend, SurePrep), and international strength. Thomson Reuters highlights its strategy around "fiduciary‑grade AI"—an emphasis on authoritative proprietary content, deep domain expertise, data privacy/governance, and customer support—plus progress on its proprietary legal LLM (Thomson) that is outperforming frontier models on specific legal tasks. The percent of annualized contract value (ACV) from Gen‑AI-enabled products reached 30% (from 28% last quarter). Capital allocation: 10% dividend increase in February, $262M repurchased in Q1, completion of a $605M return of capital and share consolidation (reducing share count ~2%), and remaining NCIB capacity planned for Q2; management reiterates balanced allocation with >$9B estimated capital capacity through 2028. Leadership: long-time CFO Mike Eastwood is retiring and incoming CFO Gary Bischoping will join. Near-term items to monitor: LLM costs (growing but still a relatively small line item), seasonality in Tax/Audit/Accounting (Q2 margin dip expected), government legal growth remaining subdued near term, and continued product commercialization / change management for AI adoption.
Sign In
Buy TRI